GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlobeStar Therapeutics Corp (OTCPK:GSTC) » Definitions » Cyclically Adjusted PB Ratio

GlobeStar Therapeutics (GlobeStar Therapeutics) Cyclically Adjusted PB Ratio : (As of May. 26, 2024)


View and export this data going back to 2011. Start your Free Trial

What is GlobeStar Therapeutics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


GlobeStar Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for GlobeStar Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlobeStar Therapeutics Cyclically Adjusted PB Ratio Chart

GlobeStar Therapeutics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

GlobeStar Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of GlobeStar Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, GlobeStar Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlobeStar Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GlobeStar Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where GlobeStar Therapeutics's Cyclically Adjusted PB Ratio falls into.



GlobeStar Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

GlobeStar Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, GlobeStar Therapeutics's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.001/129.4194*129.4194
=-0.001

Current CPI (Dec. 2023) = 129.4194.

GlobeStar Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201403 -1.040 99.695 -1.350
201406 -0.385 100.560 -0.495
201409 -0.406 100.428 -0.523
201412 -0.464 99.070 -0.606
201503 -0.457 99.621 -0.594
201506 -0.599 100.684 -0.770
201509 0.001 100.392 0.001
201512 -0.008 99.792 -0.010
201603 -0.023 100.470 -0.030
201606 -0.014 101.688 -0.018
201609 -0.114 101.861 -0.145
201612 -0.104 101.863 -0.132
201703 -0.103 102.862 -0.130
201706 -0.099 103.349 -0.124
201709 -0.079 104.136 -0.098
201712 -0.072 104.011 -0.090
201803 -0.069 105.290 -0.085
201806 -0.062 106.317 -0.075
201809 -0.056 106.507 -0.068
201812 -0.045 105.998 -0.055
201903 -0.038 107.251 -0.046
201906 -0.034 108.070 -0.041
201909 -0.031 108.329 -0.037
201912 -0.003 108.420 -0.004
202003 -0.002 108.902 -0.002
202006 -0.002 108.767 -0.002
202009 -0.002 109.815 -0.002
202012 -0.002 109.897 -0.002
202103 -0.001 111.754 -0.001
202106 -0.001 114.631 -0.001
202109 -0.001 115.734 -0.001
202112 -0.001 117.630 -0.001
202203 -0.002 121.301 -0.002
202206 -0.001 125.017 -0.001
202209 -0.002 125.227 -0.002
202212 -0.002 125.222 -0.002
202303 -0.002 127.348 -0.002
202306 -0.001 128.729 -0.001
202309 -0.001 129.860 -0.001
202312 -0.001 129.419 -0.001

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


GlobeStar Therapeutics  (OTCPK:GSTC) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


GlobeStar Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of GlobeStar Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


GlobeStar Therapeutics (GlobeStar Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
719 Jadewin Avenue, Richland, WA, USA, 99352
GlobeStar Therapeutics Corp is a clinical-stage Pharmaceutical Company introducing a patented formulation of previously approved drugs for the treatment of Multiple Sclerosis. The company is focused on developing therapies for people with serious and life-threatening rare disorders.
Executives
James C Katzaroff director, officer: CEO 719 JADWIN AVE., RICHLAND WA 99352
William J Farley director 468 ALBERN AVE, OCEANSIDE NY 11572
Robert Chicoski officer: CFO 145 NEWTON ROAD, HAVERHILL MA 01830
Alex K Blankenship director, officer: CEO, Pres., Secr., Treas. 14001 WALDEN RD., SUITE 600, MONTGOMERY TX 77356
Brent Atwood 10 percent owner 5000 RIVERSIDE DR STE100E, IRVING TX 75039
Bruce C Badeau director 770 S. POST OAK LN., STE. 360, HOUSTON TX 77056
Robert W Fryer director 1520 ENCLAVE, # 1208, HOUSTON TX 77077
Robert Federowicz director, officer: Interim CEO & Chairman 495 GRAND BLVD., SUITE 206, MIRAMAR BEACH FL 32550

GlobeStar Therapeutics (GlobeStar Therapeutics) Headlines

From GuruFocus

eQuine Holdings Discloses 8% Stake In AngioSoma (SOAN)

By PRNewswire PRNewswire 12-29-2018